PHASE I STUDY TO EVALUATE THE SAFETY OF CELLULAR ADOPTIVE IMMUNOTHERAPY, CD4+

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。本研究评价CD4+ T细胞输注的安全性、生存期及抗肿瘤效果。CD4 + T细胞自身产生生长因子，输注后可存活较长时间。这是一项剂量递增研究，在该研究中，针对黑色素瘤细胞上发现的抗原，CD4 T细胞的剂量不断增加，并以三种不同的水平给予。本研究的结局指标包括毒性、输注后T细胞存活、肿瘤缩小、T细胞输注后肿瘤靶向抗原表达的丧失。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The safety, survival and anti-tumor effect of infusions of CD4+ T cells are evaluated in this study. CD4 + T cells produce their own growth factors and may survive for prolonged periods after infusion. This is a dose escalation study in which increasing doses of CD4 T cells targeting an antigen found on melanoma cells are given at three different levels. Outcome measures for this study include toxicity, T cell survival after infusion, tumor shrinkage, and loss of targeted antigen expression by the tumor after T cell infusion.